Patent applications that contain nucleotide and/or amino acid sequence disclosures must include a copy of the sequence listing in accordance with the requirements in 37 CFR 1.821-1.825 and World Intellectual Property Organization (WIPO) Standard ST.25 (1998). Applicants may submit sequence listings for both U.S. and international patent applications. The sequence listings may be submitted on paper, compact disc, or electronically over the Internet. The USPTO uses the sequence listings to determine the patentability of the associated patent application and to support the publication of applications and issued patents. Applicants use sequence data when preparing biotechnology patent applications and may also search sequence listings after publication.
For this renewal, the USPTO estimates that the annual responses and burden hours will decrease. The net decrease in burden hours is due to administrative adjustments based on expected filings, with expected decreases in filing sequence listings on paper and CD being partially offset by expected increases in filing sequence listings electronically. The USPTO also estimates that the annual (non-hour) cost burden for this collection will have a net decrease involving both program changes and administrative adjustments. The program change is from the addition of application size fees and results in an increase of $416,250 in annual cost burden, but this increase is offset by a larger overall net decrease in other annual costs due to administrative adjustments, primarily from decreases in other filing fees and postage costs based on expected overall decreases in filings.
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
0024-JS-final.doc
PCT Rule 13ter.pdf
Sequence Listing in Application (paper)